Vaxcyte, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Vaxcyte, Inc. on June 12, 2025. The filing details the voting results for director elections, auditor ratification, executive compensation, and a corporate charter amendment.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Four matters were submitted to a vote of security holders:
- Director Elections (Class II): Three nominees were re-elected to serve until the 2028 Annual Meeting.
- John Furey: 120,748,379 For; 365,989 Withheld.
- Jacks Lee: 107,272,337 For; 13,842,031 Withheld.
- Heath Lukatch, Ph.D.: 99,231,889 For; 21,882,479 Withheld.
- Auditor Ratification: Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025 (124,849,714 For; 245,362 Against).
- Executive Compensation: The non-binding advisory resolution on named executive officer compensation was approved (77,119,045 For; 43,969,206 Against).
- Charter Amendment: The amendment to the Amended and Restated Certificate of Incorporation to provide for officer exculpation under Delaware law was approved (112,270,039 For; 8,815,788 Against).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors. The document is limited to the procedural results of the stockholder meeting.
Investor Verification Checklist
- Verify the significant number of votes withheld for directors Jacks Lee and Heath Lukatch compared to John Furey.
- Note the substantial "Against" votes (approx. 44 million) on the executive compensation advisory proposal.
- Confirm the implementation timeline for the officer exculpation charter amendment.
- Review the full proxy statement for context on the director nominees and compensation rationale not included in this 8-K.